Table 1. Proportions of various virological responses of HCV-2a- and HCV-2b-infected patients treated with PEG-IFN/RBV.
| Response | Proportion | ||
| HCV-2a | HCV-2b | All | |
| RVR | 46/61* (75%) | 34/51 (67%) | 80/112 (71%) |
| Non-RVR | 15/61 (25%) | 17/51 (33%) | 32/112 (29%) |
| EVR | 61/61 (100%) | 51/51 (100%) | 112/112 (100%) |
| ETR | 61/61 (100%) | 50/51 (98%) | 111/112 (99%) |
| SVR | 49/58 (84%) | 34/47 (72%) | 83/105 (79%) |
| Non-SVR | 9/58 (16%) | 13/47 (28%) | 22/105 (21%) |
*No. of patients/no. of total.
Abbreviations: RVR, rapid virological response; EVR, early virological response; ETR, end-of-treatment response; SVR, sustained virological response.